Europe Transient Protein Expression Market Forecast to 2031 - Regional Analysis - by Product Type, Application, and End User

The Europe transient protein expression market was valued at US$ 247.78 million in 2023 and is expected to reach US$ 386.23 million by 2031; it is estimated to register a CAGR of 5.7% from 2023 to 2031.

Increasing Applications of Protein Expression Systems Drive Europe Transient Protein Expression Market

Animal and plant cell-based transient protein expression systems have been in use for the last three decades. Significant advancements in proteomics in recent years have resulted in the availability of newer recombinant protein varieties. The practicality and reproducibility of transient protein expression in animal and plant cells encourage research and development activities to extend their applications in human cell lines.

Many contract research and development organizations as well as biopharmaceutical companies, among others, have focused their efforts on incorporating transient protein expression into their production processes. This type of expression system allows them to use different genes to create recombinant proteins without relying on the development of stable cell lines.

Temporary protein expression process finds widespread application in the manufacturing of growth factors, cytokines, hormones, blood products, modified human proteins, and monoclonal antibodies. Moreover, the creation and use of effective bioprocessing techniques have become essential for the commercial synthesis of recombinant proteins with significant therapeutic value.

Recent developments in the field of bioprocessing are being applied to provide efficient methods for generating recombinant proteins. Modern Quality by Design concepts, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, high-throughput devices for efficient bioprocess optimization, disposable systems, and process analytics technologies for higher yields of high-quality products are among the recent developments.

Transient protein expression platforms are increasingly being used in vaccine development applications since the onset of the COVID-19 pandemic. Various researchers began studying the SARS-CoV-2 and its variants extensively by using transient protein expression systems. For instance, in March-April 2020, Absolute Antibody (UK) scaled up the production of multigram quantities of different anti-SARS-CoV-2 spike proteins to aid in the development of neutralizing antibodies. Similarly, transient protein expression systems were widely used to produce positive control proteins as a part of the in-vitro diagnostics kits development processes. Thus, the increasing applications of protein expression systems fuel the transient protein expression market growth.

Europe Transient Protein Expression Market Overview

The Europe transient protein expression market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy are expected to account for a significant share of the market in the region during the forecast period. The transient protein expression market in countries such as France, the UK, and Spain is likely to experience lucrative opportunities in the upcoming years. Growing R&D activities, rising adoption of newer techniques in biotech research, and increasing investments in the biotechnology sectors drive the transient protein expression market in Europe.

Europe Transient Protein Expression Market Revenue and Forecast to 2031 (US$ Million)

Europe Transient Protein Expression Market Segmentation

The Europe transient protein expression market is categorized into product type, application, end user, and country.

• Based on product type, the Europe transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held the largest market share in 2023.
• In terms of application, the Europe transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held the largest market share in 2023.
• Based on end user, the Europe transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held the largest market share in 2023.
• By country, the Europe transient protein expression market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe transient protein expression market share in 2023.

Thermo Fisher Scientific Inc, Merck KGaA, QIAGEN NV, GenScript Biotech Corporation, Promega Corp, Takara Bio Inc, New England Biolabs, Agilent Technologies Inc, Mirus Bio LLC, Bio-Rad Laboratories Inc, Lonza Group AG, and MaxCyte Inc are some of the leading companies operating in the Europe transient protein expression market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe transient protein expression market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the Europe transient protein expression market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe transient protein expression market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.